News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Oct 11, 2023, 21:48

Elsa Anagnostou: Pleased to see stage 1 of our ctDNA molecular response adaptive clinical trial in print.

Elsa Anagnostou, Director of Thoracic Oncology Biorepository and Associate Professor of Oncology at Johns Hopkins Medicine, made the following post on Twitter:

“Hot off the press in Nature Medicine: Pleased to see stage 1 of our ctDNA molecular response adaptive clinical trial in print, supporting the value of ctDNA as an early endpoint of immunotherapy response for patients with lung cancer.”

Elsa Anagnostou: Pleased to see stage 1 of our ctDNA molecular response adaptive clinical trial in print.

For details click here.
Source: Elsa Anagnostou/Twitter

cancer clinical trials ctDNA Elsa Anagnostou immunotherapy Lung cancer Nature Medicine OncoDaily Oncology Research
Special Coverage
Blog
Mar 30, 2025, 18:31
Matthew Kurian: Happy Doctors’ Day to all the incredible physicians
Blog
Mar 30, 2025, 18:26
Indiana’s first mobile lung screening program is officially on the road - IU Simon Comprehensive Cancer Center
Blog
Mar 30, 2025, 18:14
Join the Richard and Alice Bucher Emerald Circle and help create a world without pediatric cancers - St. Baldrick's Foundation
Blog
Mar 30, 2025, 18:01
Philippe Spiess: Always an honor to deliver an update in the management of bladder cancer with Tom Flaig
Blog
Mar 30, 2025, 17:46
Thought-provoking trial on localized pancreatic cancer presented by Ethan Agritelley at SSO2025 - Duke Surgical Oncology
Blog
Mar 30, 2025, 17:44
Addressing Gaps in Awareness, Care, and Support for the Early-Age Onset Digestive Cancer Community - European Cancer Organisation
Blog
Mar 30, 2025, 17:34
Olga Kantor: Fantastic presentation by Monika Masanam on MIBC after NST at SSO2025
Blog
Mar 30, 2025, 17:19
Carlos Ayala-Navarro on the immune microenvironment in appendiceal cancers - Moffitt Cancer Center
Blog
Mar 30, 2025, 17:19
Roupen Odabashian: Comparing Research Compensation - Healthcare vs AI
Blog
Mar 30, 2025, 17:05
Julien Mazieres: Heterogeneity of resistance mechanisms should lead to a personalized strategy
Blog
Mar 30, 2025, 16:56
Joe Chang: Optimal first-line treatment for EGFR-mutated mNSCLC
Positive
Mar 30, 2025, 16:44
Yüksel Ürün: FDA approves neoadjuvant and adjuvant durvalumab in MIBC